← Back to headlines
Pfizer Acquires Rights for Obesity Drug in China for $495M
Pfizer has finalized a deal worth $495 million to secure the rights for an obesity drug in China, expanding its pharmaceutical presence in the region.
24 Feb, 04:34 — 24 Feb, 04:34
Sources
Showing 1 of 1 sources
